Trial Profile
A study investigating incidences of De Novo donor specific antibodies (DSA) after Alemtuzumab induction in renal transplant recipients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2016
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 14 Oct 2016 New trial record